3.1-Primary outcome measures
Compared with LFO, the time that
HR and RR baseline values reached their normal range for age was shorter
in HFNCO therapy (2.0 h [1.0-4.0] vs. 12.0 h [2.0-24.0] and 4.0
h [2.0-12.0] vs. 24.0 h [4.0-48.0], respectively; P< .001); additionally, the improvement in CRS emerged more
quickly in children treated with HFNCO (2.0 h [1.0-4.0] vs. 4.0 h
[2.0-24.0]; P = .003; Table 2). The cumulative number of
patients with normal HR and RR for age over time and those whose CRS
regressed to a lower severity score was presented in Figure 2-4,
respectively.